Taisho Pharmaceutical Swings To Quarterly Loss
This article was originally published in PharmAsia News
Taisho revised its estimated business results for the first half of fiscal year 2008. Instead of ¥9.5 billion in profit, the company now estimates ¥1 billion in loss. The revision is a reflection of a ¥13.3 billion loss due to share price reduction in Taisho's subsidiary Biofermin. Taisho also reduced its net profit for the full fiscal year to ¥10.5 billion from previous estimates of ¥22.5 billion. (Click here for more - Japanese language
You may also be interested in...
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.
A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.